• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cardlytics Announces Fourth Quarter and Full Year 2024 Financial Results

    3/12/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology
    Get the next $CDLX alert in real time by email

    Cardlytics, Inc. (NASDAQ:CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2024.

    "While 2024 was a challenging year for Cardlytics, we nevertheless planted the seeds and refocused our efforts to get back on track for growth this year," said Amit Gupta, CEO of Cardlytics. "We remain grounded in our vision for long-term and sustainable growth. We are focused on strengthening our competitive moat through our efforts to modernize our platform, enhance our product and tech capabilities, and expand our network of partners and advertisers."

    "In 2025, we are focused on delivering sequential improvements and positive Adjusted EBITDA," said Alexis DeSieno, CFO of Cardlytics. "We remain confident in our ability to invest in our business while also satisfying all of our financial obligations."

    Fourth Quarter 2024 Financial Results

    • Total Revenue was $74.0 million, a decrease of 17.0% compared to $89.2 million in the fourth quarter of 2023, or a decrease of 16.0% excluding Entertainment.
    • Billings, a non-GAAP metric, was $116.3 million, a decrease of 11.9% compared to $131.9 million in the fourth quarter of 2023, or a decrease of 11.2% excluding Entertainment.
    • Adjusted Contribution, a non-GAAP metric, was $40.7 million, a decrease of 13.9% compared to $47.3 million in the fourth quarter of 2023, or a decrease of 12.0% excluding Entertainment.
    • Net Loss was $(15.6) million, or $(0.31) per diluted share, based on 51.0 million weighted-average common shares outstanding, compared to a Net Loss of $(100.8) million, or $(2.56) per diluted share, based on 39.5 million weighted-average common shares outstanding in the fourth quarter of 2023.
    • Adjusted EBITDA, a non-GAAP metric, was $6.4 million, a decrease of $3.6 million compared to $10.0 million in the fourth quarter of 2023, or a decrease of $3.9 million excluding Entertainment.
    • Adjusted Net Income, a non-GAAP metric, was $0.2 million, or $0.00 per diluted share, based on 51.0 million weighted-average common shares outstanding in the fourth quarter of 2024, compared to an Adjusted Net Income of $5.7 million, or $0.14 per diluted share, based on 39.5 million weighted-average common shares outstanding in the fourth quarter of 2023.
    • Net cash provided by operating activities was $3.0 million, an increase of $0.1 million compared to net cash provided by operating activities of $2.9 million in the fourth quarter of 2023.
    • Free Cash Flow, a non-GAAP metric, was $(1.5) million, a decrease of $(0.7) million compared to $(0.8) million in the fourth quarter of 2023.

    Fiscal Year 2024 Financial Results

    • Total Revenue was $278.3 million, a decrease of 10.0% compared to $309.2 million in 2023, or a decrease of 8.0% excluding Entertainment.
    • Billings, a non-GAAP metric, was $443.8 million, a decrease of 2.1% compared to $453.4 million in 2023, or a decrease of 0.7% excluding Entertainment.
    • Adjusted Contribution, a non-GAAP metric, was $150.5 million, a decrease of 5.1% compared to $158.6 million in 2023, or a decrease of 1.0% excluding Entertainment.
    • Net Loss was $(189.3) million, or $(3.91) per diluted share, based on 48.4 million weighted-average common shares outstanding, compared to a Net Loss of $(134.7) million, or $(3.69) per diluted share, based on 36.5 million weighted-average common shares outstanding in 2023.
    • Adjusted EBITDA, a non-GAAP metric, was $2.5 million, a decrease of $1.2 million compared to $3.8 million in 2023, or a decrease of $1.9 million excluding Entertainment.
    • Adjusted Net Loss, a non-GAAP metric, was $(18.9) million, or $(0.39) per diluted share, based on 48.4 million weighted-average common shares outstanding in 2024, compared to an Adjusted Net Loss of $(11.4) million, or $(0.31) per diluted share, based on 36.5 million weighted-average common shares outstanding in 2023.
    • Net cash used in operating activities was $(8.8) million, a decrease of $(8.6) million compared to $(0.2) million in 2023.
    • Free Cash Flow, a non-GAAP metric, was $(28.1) million a decrease of $(15.5) million compared to $(12.6) million in 2023.

    Key Metrics

    • Cardlytics MAUs in the quarter were 167.3 million, a decrease of 0.4% compared to 168.0 million in the fourth quarter of 2023. For full year 2024, Cardlytics MAUs were 166.9 million, an increase of 3.0% compared to 162.1 million in 2023.
    • Cardlytics ARPU was $0.44, a decrease of 16.7% compared to $0.53 in the fourth quarters for 2024 and 2023. For the full year 2024 Cardlytics ARPU was $1.67, a decrease of 12.6% compared to $1.91 in 2023.

    Definitions of MAUs and ARPU are included below under the caption "Non-GAAP Measures and Other Performance Metrics."

    CARDLYTICS, INC.

    SUMMARY OF GAAP AND NON-GAAP RESULTS (UNAUDITED)

    (Dollars in thousands)

     

     

    Three Months Ended December 31,

     

     

     

    2024

     

    2023

     

    2023 Results

    Excluding

    Entertainment(2)

     

    Change %

     

    Change %

    Excluding

    Entertainment(2)

    Billings(1)

    $

    116,279

     

     

    $

    131,947

     

     

    $

    130,914

     

     

     

    (11.9

    )%

     

     

    (11.2

    )%

    Consumer Incentives

     

    42,283

     

     

     

    42,780

     

     

     

    42,780

     

     

     

    (1.2

    )%

     

     

    (1.2

    )%

    Revenue

     

    73,996

     

     

     

    89,167

     

     

     

    88,134

     

     

     

    (17.0

    )%

     

     

    (16.0

    )%

    Partner Share and other third-party costs

     

    33,285

     

     

     

    41,880

     

     

     

    41,863

     

     

     

    (20.5

    )%

     

     

    (20.5

    )%

    Adjusted Contribution(1)

     

    40,711

     

     

     

    47,287

     

     

     

    46,271

     

     

     

    (13.9

    )%

     

     

    (12.0

    )%

    Delivery costs

     

    7,979

     

     

     

    7,797

     

     

     

    7,797

     

     

     

    2.3

    %

     

     

    2.3

    %

    Gross Profit

    $

    32,732

     

     

    $

    39,490

     

     

    $

    38,474

     

     

     

    (17.1

    )%

     

     

    (14.9

    )%

    Net Loss

    $

    (15,590

    )

     

    $

    (100,838

    )

     

    $

    (96,557

    )

     

    $

    80,967

     

     

    $

    80,967

     

    Adjusted EBITDA(1)

    $

    6,398

     

     

    $

    9,987

     

     

    $

    10,315

     

     

    $

    (3,917

    )

     

    $

    (3,917

    )

     

     

     

     

     

     

     

     

     

     

    Adjusted Contribution

     

     

     

     

     

     

     

     

     

    % of Billings

     

    35.0

    %

     

     

    35.8

    %

     

     

    35.3

    %

     

     

     

     

    % of Revenue

     

    55.0

    %

     

     

    53.0

    %

     

     

    52.5

    %

     

     

     

     

    Adjusted EBITDA

     

     

     

     

     

     

     

     

     

    % of Billings

     

    5.5

    %

     

     

    7.6

    %

     

     

    7.9

    %

     

     

     

     

    % of Revenue

     

    8.6

    %

     

     

    11.2

    %

     

     

    11.7

    %

     

     

     

     

    (1)

    Billings, Adjusted Contribution and Adjusted EBITDA are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings," "Reconciliation of GAAP Gross Profit to Adjusted Contribution" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA."

    (2)

    The column excludes results from the Entertainment business. We sold and transferred substantially all of the assets of Entertainment in December 2023.

     

    Year Ended December 31,

     

     

     

    2024

     

    2023

     

    2023 Results

    Excluding

    Entertainment(2)

     

    Change %

     

    Change %

    Excluding

    Entertainment(2)

    Billings(1)

    $

    443,840

     

     

    $

    453,426

     

     

    $

    446,801

     

     

     

    (2.1

    )%

     

     

    (0.7

    )%

    Consumer Incentives

     

    165,542

     

     

     

    144,222

     

     

     

    144,222

     

     

     

    14.8

    %

     

     

    14.8

    %

    Revenue

     

    278,298

     

     

     

    309,204

     

     

     

    302,579

     

     

     

    (10.0

    )%

     

     

    (8.0

    )%

    Partner Share and other third-party costs

     

    127,761

     

     

     

    150,578

     

     

     

    150,469

     

     

     

    (15.2

    )%

     

     

    (15.1

    )%

    Adjusted Contribution(1)

     

    150,537

     

     

     

    158,626

     

     

     

    152,110

     

     

     

    (5.1

    )%

     

     

    (1.0

    )%

    Delivery costs

     

    29,643

     

     

     

    28,248

     

     

     

    28,248

     

     

     

    4.9

    %

     

     

    4.9

    %

    Gross Profit

    $

    120,894

     

     

    $

    130,378

     

     

    $

    123,862

     

     

     

    (7.3

    )%

     

     

    (2.4

    )%

    Net Loss

    $

    (189,304

    )

     

    $

    (134,702

    )

     

    $

    (127,967

    )

     

    $

    (54,602

    )

     

    $

    (61,337

    )

    Adjusted EBITDA(1)

    $

    2,523

     

     

    $

    3,771

     

     

    $

    4,442

     

     

    $

    (1,248

    )

     

    $

    (1,919

    )

     

     

     

     

     

     

     

     

     

     

    Adjusted Contribution

     

     

     

     

     

     

     

     

     

    % of Billings

     

    33.9

    %

     

     

    35.0

    %

     

     

    34.0

    %

     

     

     

     

    % of Revenue

     

    54.1

    %

     

     

    51.3

    %

     

     

    50.3

    %

     

     

     

     

    Adjusted EBITDA

     

     

     

     

     

     

     

     

     

    % of Billings

     

    0.6

    %

     

     

    0.8

    %

     

     

    1.0

    %

     

     

     

     

    % of Revenue

     

    0.9

    %

     

     

    1.2

    %

     

     

    1.5

    %

     

     

     

     

    (1)

    Billings, Adjusted Contribution and Adjusted EBITDA are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings," "Reconciliation of GAAP Gross Profit to Adjusted Contribution" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA."

    (2)

    The column excludes results from the Entertainment business. We sold and transferred substantially all of the assets of Entertainment in December 2023.

    First Quarter 2025 Financial Expectations

    Cardlytics anticipates Billings, Revenue, Adjusted Contribution and Adjusted EBITDA to be in the following ranges (in millions, except for percentage change rates):

     

    Q1 2025

    Guidance

     

    YoY Change

    Billings(1)

    $91.5 - $94.5

     

    (13%) - (10%)

    Revenue

    $57.0 - $60.0

     

    (16%) - (11%)

    Adjusted Contribution(2)

    $30.0 - $32.5

     

    (19%) - (14%)

    Adjusted EBITDA(2)

    ($7.5) - ($4.0)

     

    ($7.7) - ($4.2)

    (1)

    A reconciliation of Billings to GAAP Revenue on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP Revenue to Billings."

    (2)

    A reconciliation of Adjusted Contribution to GAAP Gross Profit and a reconciliation of Adjusted EBITDA to GAAP Net Loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.

    Earnings Teleconference Information

    Cardlytics will discuss its fourth quarter and full year 2024 financial results during a teleconference today, March 12, 2025, at 5:00 PM ET / 2:00 PM PT. Following the completion of the call, a recorded replay of the webcast will be available on Cardlytics' website.

    About Cardlytics

    Cardlytics (NASDAQ:CDLX) is a digital advertising platform. We partner with financial institutions to run their rewards programs that promote customer loyalty and deepen relationships. In turn, we have a secure view into approximately 1 of every 2 card-based transactions in the U.S., allowing us to see where and when consumers are spending their money. We use these insights to help marketers identify, reach, and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns. Headquartered in Atlanta, Cardlytics has offices in Menlo Park, Los Angeles, New York, and London. Learn more at www.cardlytics.com.

    Cautionary Language Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements related to our growth opportunity, our ability to deliver stronger execution and shareholder value, our intention to strengthen our competitive position, enhance our product and tech capabilities and expand our network of partners and advertisers and our financial guidance for the first quarter of 2025. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," or variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control.

    Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks related to unfavorable conditions in the global economy and the industries that we serve; our quarterly operating results have fluctuated and may continue to vary from period to period; our ability to sustain our revenue growth and billings; risks related to our substantial dependence on our Cardlytics platform; risks related to our substantial dependence on JPMorgan Chase Bank, National Association ("Chase"), Bank of America, National Association ("Bank of America"), Wells Fargo Bank, National Association ("Wells Fargo"), American Express Travel Related Services Company, Inc. ("American Express") and a limited number of other financial institution ("FI") partners; risks related to our ability to maintain relationships with Chase, Wells Fargo and Bank of America; the amount and timing of budgets by marketers, which are affected by budget cycles, economic conditions and other factors; our ability to generate sufficient revenue to offset contractual commitments to FI partners; our ability to attract new partners, including FI partners, and maintain relationships with bank processors and digital banking providers; our ability to maintain relationships with marketers; our ability to adapt to changing market conditions, including our ability to adapt to changes in consumer habits, negotiate fee arrangements with new and existing partners and retailers, and develop and launch new services and features; and other risks detailed in the "Risk Factors" section of our Form 10-K filed with the Securities and Exchange Commission on March 12, 2025 and in subsequent periodic reports that we file with the Securities and Exchange Commission. Past performance is not necessarily indicative of future results.

    The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Non-GAAP Measures and Other Performance Metrics

    To supplement the financial measures presented in our press release and related conference call or webcast in accordance with generally accepted accounting principles in the United States ("GAAP"), we also present the following non-GAAP measures of financial performance in this press release: Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per share and Free Cash Flow, as well as certain other performance metrics, such as monthly active users ("MAUs") and average revenue per user ("ARPU").

    A "non-GAAP financial measure" refers to a numerical measure of our historical or future financial performance or financial position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other companies and therefore should not be used to compare our performance to that of other companies.

    We have presented Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per share as non-GAAP financial measures in this press release. Billings represents the gross amount billed to customers and marketers for services in order to generate revenue. Cardlytics platform Billings is recognized gross of both Consumer Incentives and Partner Share. Cardlytics platform GAAP Revenue is recognized net of Consumer Incentives and gross of Partner Share. Bridg platform Billings is the same as Bridg platform GAAP Revenue. Adjusted Contribution measures the degree by which revenue generated from our marketers exceeds the cost to obtain the purchase data and the digital advertising space from our partners. Adjusted Contribution demonstrates how incremental Revenue on our platforms generates incremental amounts to support our sales and marketing, research and development, general and administrative and other investments. Adjusted Contribution is calculated by taking our total Revenue less our Partner Share and other third-party costs. Adjusted Contribution does not take into account all costs associated with generating Revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrative expenses and other expenses, which we do not take into consideration when making decisions on how to manage our advertising campaigns. Management views Adjusted Contribution as the most relevant metric to measure the financial performance as it reflects the dollars we keep after all of our partners are paid. Adjusted EBITDA represents our Net Loss before interest expense, net; depreciation and amortization; stock-based compensation expense; acquisition, integration and divestiture costs (benefits); change in contingent consideration; foreign currency loss (gain); impairment of goodwill and intangible assets; gain on debt extinguishment; loss on divestiture; and, in applicable periods, certain other income and expense items, such as restructuring and reduction of force; income tax benefit; and deferred implementation costs. Adjusted Net Income (Loss) as our Net Loss before stock-based compensation expense; foreign currency loss (gain); acquisition, integration and divestiture costs (benefits); amortization of acquired intangibles; change in contingent consideration; impairment of goodwill and intangible assets; gain on debt extinguishment; and loss on divestiture, in applicable periods, certain other income and expense items, such as restructuring and reduction of force and income tax benefit. We define Adjusted Net Income (Loss) per share as Adjusted Net Income (Loss) divided by our weighted-average common shares outstanding, diluted. We define Free Cash Flow as net cash used in operating activities, plus acquisition of property and equipment, capitalized software development costs and acquisition of patents. We believe free cash flow is useful to measure the funds generated in a given period that are available for distribution or to sustain the business. We believe this supplemental information enhances stockholders' ability to evaluate our performance.

    We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they eliminate items that are either not part of our core operations or do not require a cash outlay, such as stock-based compensation expense. Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing operating performance.

    We define MAUs as targetable customers that have logged in and visited online or mobile applications containing offers, opened an email containing an offer, or redeemed an offer from the Cardlytics platform during a monthly period. We then calculate a monthly average of these MAUs for the periods presented. We define ARPU as the total revenue generated in the applicable period calculated in accordance with GAAP, divided by the average number of MAUs in the applicable period.

    CARDLYTICS, INC.

    CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands, except par value amounts)

     

     

    December 31,

     

    2024

     

    2023

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    65,594

     

     

    $

    91,830

     

    Accounts receivable and contract assets, net

     

    103,252

     

     

     

    120,622

     

    Other receivables

     

    3,801

     

     

     

    5,379

     

    Prepaid expenses and other assets

     

    5,336

     

     

     

    6,097

     

    Total current assets

     

    177,983

     

     

     

    223,928

     

    Long-term assets:

     

     

     

    Property and equipment, net

     

    2,596

     

     

     

    3,323

     

    Right-of-use assets under operating leases, net

     

    6,341

     

     

     

    7,310

     

    Intangible assets, net

     

    11,371

     

     

     

    35,003

     

    Goodwill

     

    159,429

     

     

     

    277,202

     

    Capitalized software development costs, net

     

    33,341

     

     

     

    24,643

     

    Other long-term assets, net

     

    1,650

     

     

     

    2,735

     

    Total assets

    $

    392,711

     

     

    $

    574,144

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    3,689

     

     

    $

    4,425

     

    Accrued liabilities:

     

     

     

    Accrued compensation

     

    5,494

     

     

     

    11,662

     

    Accrued expenses

     

    7,175

     

     

     

    9,587

     

    Partner Share liability

     

    32,479

     

     

     

    48,867

     

    Consumer Incentive liability

     

    45,513

     

     

     

    52,678

     

    Deferred revenue

     

    2,154

     

     

     

    2,405

     

    Short-term debt

     

    45,863

     

     

     

    —

     

    Current operating lease liabilities

     

    2,025

     

     

     

    2,127

     

    Current contingent consideration

     

    4,563

     

     

     

    39,398

     

    Total current liabilities

     

    148,955

     

     

     

    171,149

     

    Long-term liabilities:

     

     

     

    Convertible senior notes, net

     

    167,729

     

     

     

    227,504

     

    Line of credit

     

    —

     

     

     

    30,000

     

    Long-term deferred revenue

     

    —

     

     

     

    67

     

    Long-term operating lease liabilities

     

    6,034

     

     

     

    6,391

     

    Long-term contingent consideration

     

    —

     

     

     

    4,162

     

    Other long-term liabilities

     

    —

     

     

     

    73

     

    Total liabilities

     

    322,718

     

     

     

    439,346

     

    Stockholders' equity:

     

     

     

    Common stock, $0.0001 par value—100,000 shares authorized and 51,257 and 39,728 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively

     

    10

     

     

     

    9

     

    Additional paid-in capital

     

    1,366,958

     

     

     

    1,243,594

     

    Accumulated other comprehensive income

     

    3,601

     

     

     

    2,467

     

    Accumulated deficit

     

    (1,300,576

    )

     

     

    (1,111,272

    )

    Total stockholders' equity

     

    69,993

     

     

     

    134,798

     

    Total liabilities and stockholders' equity

    $

    392,711

     

     

    $

    574,144

     

    CARDLYTICS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (Amounts in thousands except per share amounts)

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2024

     

    2023

     

    2024

     

    2023

    Revenue

    $

    73,997

     

     

    $

    89,167

     

     

    $

    278,298

     

     

    $

    309,204

     

    Costs and expenses:

     

     

     

     

     

     

     

    Partner Share and other third-party costs

     

    33,285

     

     

     

    41,880

     

     

     

    127,761

     

     

     

    150,578

     

    Delivery costs

     

    7,979

     

     

     

    7,797

     

     

     

    29,643

     

     

     

    28,248

     

    Sales and marketing expense

     

    11,343

     

     

     

    14,111

     

     

     

    52,649

     

     

     

    57,425

     

    Research and development expense

     

    9,895

     

     

     

    12,512

     

     

     

    49,607

     

     

     

    51,352

     

    General and administrative expense

     

    13,770

     

     

     

    13,904

     

     

     

    56,482

     

     

     

    58,810

     

    Acquisition, integration and divestiture costs (benefits)

     

    —

     

     

     

    1,833

     

     

     

    161

     

     

     

    (6,313

    )

    Change in contingent consideration

     

    100

     

     

     

    16,291

     

     

     

    210

     

     

     

    1,246

     

    Impairment of goodwill and intangible assets

     

    —

     

     

     

    70,518

     

     

     

    131,595

     

     

     

    70,518

     

    Loss on divestiture

     

    —

     

     

     

    6,550

     

     

     

    —

     

     

     

    6,550

     

    Depreciation and amortization expense

     

    5,940

     

     

     

    6,695

     

     

     

    25,689

     

     

     

    26,460

     

    Total costs and expenses

     

    82,312

     

     

     

    192,091

     

     

     

    473,797

     

     

     

    444,874

     

    Operating loss

     

    (8,315

    )

     

     

    (102,924

    )

     

     

    (195,499

    )

     

     

    (135,670

    )

    Other income (expense):

     

     

     

     

     

     

     

    Interest expense, net

     

    (1,694

    )

     

     

    (839

    )

     

     

    (5,553

    )

     

     

    (2,336

    )

    Foreign currency (loss) gain

     

    (5,581

    )

     

     

    2,925

     

     

     

    (1,269

    )

     

     

    3,304

     

    Gain on debt extinguishment

     

    —

     

     

     

    —

     

     

     

    13,017

     

     

     

    —

     

    Total other (expense) income

     

    (7,275

    )

     

     

    2,086

     

     

     

    6,195

     

     

     

    968

     

    Loss before income taxes

     

    (15,590

    )

     

     

    (100,838

    )

     

     

    (189,304

    )

     

     

    (134,702

    )

    Income tax benefit

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Net Loss

     

    (15,590

    )

     

     

    (100,838

    )

     

     

    (189,304

    )

     

     

    (134,702

    )

    Net Loss per share, basic and diluted

    $

    (0.31

    )

     

    $

    (2.56

    )

     

    $

    (3.91

    )

     

    $

    (3.69

    )

    Weighted-average common shares outstanding, basic and diluted

     

    51,005

     

     

     

    39,454

     

     

     

    48,361

     

     

     

    36,488

     

    CARDLYTICS, INC.

    STOCK-BASED COMPENSATION EXPENSE

    (Amounts in thousands)

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2024

     

    2023

     

    2024

     

    2023

    Delivery costs

    $

    641

     

    $

    627

     

    $

    2,680

     

    $

    2,427

    Sales and marketing expense

     

    1,877

     

     

    3,137

     

     

    10,017

     

     

    12,624

    Research and development expense

     

    2,926

     

     

    4,144

     

     

    14,957

     

     

    16,392

    General and administrative expense

     

    3,229

     

     

    3,116

     

     

    12,713

     

     

    9,537

    Total stock-based compensation expense

    $

    8,673

     

    $

    11,024

     

    $

    40,367

     

    $

    40,980

    CARDLYTICS, INC.

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Amounts in thousands)

     

     

    Year Ended

    December 31,

     

    2024

     

    2023

    Operating activities

     

     

     

    Net Loss

    $

    (189,304

    )

     

    $

    (134,702

    )

    Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

     

     

     

    Credit loss expense

     

    6,106

     

     

     

    1,704

     

    Depreciation and amortization

     

    25,689

     

     

     

    26,460

     

    Amortization of financing costs charged to interest expense

     

    1,633

     

     

     

    1,648

     

    Amortization of right-of-use asset

     

    2,187

     

     

     

    3,055

     

    Impairment of goodwill and intangible assets

     

    131,595

     

     

     

    70,518

     

    Loss on divestiture

     

    —

     

     

     

    6,550

     

    Gain on debt extinguishment

     

    (13,017

    )

     

     

    —

     

    Stock-based compensation expense

     

    40,367

     

     

     

    40,980

     

    Change in contingent consideration

     

    210

     

     

     

    1,246

     

    Other non-cash expense (income), net

     

    1,481

     

     

     

    (4,170

    )

    Change in operating assets and liabilities:

     

     

     

    Accounts receivable and contracts assets, net

     

    12,497

     

     

     

    (7,725

    )

    Prepaid expenses and other assets

     

    1,360

     

     

     

    2,492

     

    Accounts payable

     

    499

     

     

     

    239

     

    Other accrued expenses

     

    (6,644

    )

     

     

    (7,492

    )

    Partner Share liability

     

    (16,350

    )

     

     

    405

     

    Customer Incentive liability

     

    (7,133

    )

     

     

    (1,393

    )

    Net cash used in operating activities

     

    (8,824

    )

     

     

    (185

    )

    Investing activities

     

     

     

    Acquisition of property and equipment

     

    (1,562

    )

     

     

    (667

    )

    Capitalized software development costs

     

    (17,736

    )

     

     

    (11,725

    )

    Proceeds from divestitures, net of cash divested

     

    552

     

     

     

    2,330

     

    Net cash used in investing activities

     

    (18,746

    )

     

     

    (10,062

    )

    Financing activities

     

     

     

    Proceeds from issuance of debt

     

    172,500

     

     

     

    30,000

     

    Principal payments of debt

     

    (199,303

    )

     

     

    (31

    )

    Proceeds from termination of capped calls related to convertible notes

     

    115

     

     

     

    —

     

    Proceeds from issuance of common stock

     

    48,645

     

     

     

    55

     

    Settlement of contingent consideration

     

    (14,167

    )

     

     

    (50,050

    )

    Deferred equity issuance costs

     

    (309

    )

     

     

    —

     

    Debt issuance costs

     

    (6,037

    )

     

     

    —

     

    Net cash provided by (used in) financing activities

     

    1,444

     

     

     

    (20,026

    )

    Effect of exchange rates on cash, cash equivalents and restricted cash

     

    (110

    )

     

     

    118

     

    Net decrease in cash, cash equivalents and restricted cash

     

    (26,236

    )

     

     

    (30,155

    )

    Cash, cash equivalents, and restricted cash — Beginning of period

     

    91,830

     

     

     

    121,985

     

    Cash, cash equivalents, and restricted cash — End of period

    $

    65,594

     

     

    $

    91,830

     

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP REVENUE TO BILLINGS

    (Amounts in thousands)

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2024

     

    2023

     

    2024

     

    2023

    Revenue

    $

    73,996

     

    $

    89,167

     

    $

    278,298

     

    $

    309,204

    Plus:

     

     

     

     

     

     

     

    Consumer Incentives

     

    42,283

     

     

    42,780

     

     

    165,542

     

     

    144,222

    Billings

    $

    116,279

     

    $

    131,947

     

    $

    443,840

     

    $

    453,426

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED CONTRIBUTION

    (Amounts in thousands)

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2024

     

    2023

     

    2023

     

    2022

    Revenue

    $

    73,996

     

    $

    89,167

     

    $

    278,298

     

    $

    309,204

    Minus:

     

     

     

     

     

     

     

    Partner Share and other third-party costs

     

    33,285

     

     

    41,880

     

     

    127,761

     

     

    150,578

    Delivery costs(1)

     

    7,979

     

     

    7,797

     

     

    29,643

     

     

    28,248

    Gross Profit

     

    32,732

     

     

    39,490

     

     

    120,894

     

     

    130,378

    Plus:

     

     

     

     

     

     

     

    Delivery costs(1)

     

    7,979

     

     

    7,797

     

     

    29,643

     

     

    28,248

    Adjusted Contribution

    $

    40,711

     

    $

    47,287

     

    $

    150,537

     

    $

    158,626

    (1)

    Stock-based compensation expense recognized in delivery costs totaled $0.6 million and $0.6 million during the three months ended December 31, 2024 and 2023, respectively. Stock-based compensation expense recognized in consolidated delivery costs totaled $2.7 million and $2.4 million during the year ended December 31, 2024 and 2023, respectively.

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

    (Amounts in thousands)

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2024

     

    2023

     

    2024

     

    2023

    Net Loss

    $

    (15,590

    )

     

    $

    (100,838

    )

     

    $

    (189,304

    )

     

    $

    (134,702

    )

    Plus:

     

     

     

     

     

     

     

    Interest expense, net

     

    1,694

     

     

     

    839

     

     

     

    5,553

     

     

     

    2,336

     

    Depreciation and amortization

     

    5,940

     

     

     

    6,695

     

     

     

    25,689

     

     

     

    26,460

     

    Stock-based compensation expense

     

    8,673

     

     

     

    11,024

     

     

     

    40,367

     

     

     

    40,980

     

    Acquisition, integration and divestiture costs (benefits)

     

    —

     

     

     

    1,833

     

     

     

    161

     

     

     

    (6,313

    )

    Change in contingent consideration

     

    100

     

     

     

    16,291

     

     

     

    210

     

     

     

    1,246

     

    Foreign currency loss (gain)

     

    5,581

     

     

     

    (2,925

    )

     

     

    1,269

     

     

     

    (3,304

    )

    Impairment of goodwill and intangible assets

     

    —

     

     

     

    70,518

     

     

     

    131,595

     

     

     

    70,518

     

    Gain on debt extinguishment

     

    —

     

     

     

    —

     

     

     

    (13,017

    )

     

     

    —

     

    Loss on divestiture

     

    —

     

     

     

    6,550

     

     

     

    —

     

     

     

    6,550

     

    Adjusted EBITDA

    $

    6,398

     

     

    $

    9,987

     

     

    $

    2,523

     

     

    $

    3,771

     

    CARDLYTICS, INC.

    RECONCILIATION OF GAAP NET LOSS TO ADJUSTED NET INCOME (LOSS) AND ADJUSTED NET INCOME (LOSS) PER SHARE

    (Amounts in thousands except per share amounts)

     
     

     

    Three Months

    Ended December 31,

     

    Year Ended

    December 31,

     

    2024

     

    2023

     

    2024

     

    2023

    Net Loss

    $

    (15,590

    )

     

    $

    (100,838

    )

     

    $

    (189,304

    )

     

    $

    (134,702

    )

    Plus:

     

     

     

     

     

     

     

    Stock-based compensation expense

     

    8,673

     

     

     

    11,024

     

     

     

    40,367

     

     

     

    40,980

     

    Foreign currency loss (gain)

     

    5,581

     

     

     

    (2,925

    )

     

     

    1,269

     

     

     

    (3,304

    )

    Acquisition, integration and divestiture costs (benefits)

     

    —

     

     

     

    1,833

     

     

     

    161

     

     

     

    (6,313

    )

    Amortization of acquired intangibles

     

    1,455

     

     

     

    3,258

     

     

     

    9,810

     

     

     

    13,589

     

    Change in contingent consideration

     

    100

     

     

     

    16,291

     

     

     

    210

     

     

     

    1,246

     

    Impairment of goodwill and intangible assets

     

    —

     

     

     

    70,518

     

     

     

    131,595

     

     

     

    70,518

     

    Gain on debt extinguishment

     

    —

     

     

     

    —

     

     

     

    (13,017

    )

     

     

    —

     

    Loss on divestiture

     

    —

     

     

     

    6,550

     

     

     

    —

     

     

     

    6,550

     

    Adjusted Net Income (Loss)

    $

    219

     

     

    $

    5,711

     

     

    $

    (18,909

    )

     

    $

    (11,436

    )

    Weighted-average number of shares of common stock used in computing Adjusted Net Income (Loss) per share:

     

     

     

     

     

     

     

    Weighted-average common shares outstanding, diluted

     

    51,005

     

     

     

    39,454

     

     

     

    48,361

     

     

     

    36,488

     

    Adjusted Net Income (Loss) per share, diluted

    $

    —

     

     

    $

    0.14

     

     

    $

    (0.39

    )

     

    $

    (0.31

    )

    CARDLYTICS, INC.

    RECONCILIATION OF NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES TO FREE CASH FLOW

    (Amounts in thousands)

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2024

     

    2023

     

    2024

     

    2023

    Net cash provided by (used in) operating activities

    $

    2,977

     

     

    $

    2,934

     

     

    $

    (8,824

    )

     

    $

    (185

    )

    Plus:

     

     

     

     

     

     

     

    Acquisition of property and equipment

     

    (123

    )

     

     

    (274

    )

     

     

    (1,562

    )

     

     

    (667

    )

    Capitalized software development costs

     

    (4,313

    )

     

     

    (3,423

    )

     

     

    (17,736

    )

     

     

    (11,725

    )

    Free Cash Flow

    $

    (1,459

    )

     

    $

    (763

    )

     

    $

    (28,122

    )

     

    $

    (12,577

    )

    CARDLYTICS, INC.

    RECONCILIATION OF FORECASTED GAAP REVENUE TO BILLINGS

    (Amounts in millions)

     

     

    Q1 2025

    Guidance

    Revenue

    $57.0 - $60.0

    Plus:

     

    Consumer Incentives

    $31.5 - $37.5

    Billings

    $91.5 - $94.5

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250312734038/en/

    Public Relations:

    [email protected]

    Investor Relations:

    [email protected]

    Get the next $CDLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDLX

    DatePrice TargetRatingAnalyst
    10/11/2024$4.00In-line
    Evercore ISI
    8/16/2024$5.00Outperform → Market Perform
    Northland Capital
    8/15/2024$4.00 → $3.50Neutral → Underperform
    BofA Securities
    8/8/2024Buy → Hold
    Craig Hallum
    8/8/2024Buy → Hold
    Needham
    8/8/2024$18.00 → $5.00Buy → Hold
    Lake Street
    6/20/2024$11.00Neutral
    BofA Securities
    6/18/2024$14.00Outperform
    Northland Capital
    More analyst ratings

    $CDLX
    Financials

    Live finance-specific insights

    See more
    • Cardlytics Announces First Quarter 2025 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2025. "We've made marked progress across our key business pillars, which continue to underpin our journey to 'platformize' Cardlytics and position ourselves as the leading commerce media platform," said Amit Gupta, CEO of Cardlytics. "Our expanding ecosystem, depth and breadth of our data, and ongoing tech investments are strengthening our position and providing differentiated value to our partners and advertisers." "We've built a resilient platform and are making strategic decisions as we look to future-proof our business," said Alexis DeSieno, CFO of Ca

      5/7/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces Timing of Its First Quarter 2025 Earnings Release

      Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the first quarter ending March 31, 2025 will be released on May 7, 2025, after market close. Conference Call Details: When: May 7, 2025 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. Dial-in: Call participants may dial +1 800-549-8228 and use Conference ID: 86123. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party purchase data, that

      4/23/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces Fourth Quarter and Full Year 2024 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2024. "While 2024 was a challenging year for Cardlytics, we nevertheless planted the seeds and refocused our efforts to get back on track for growth this year," said Amit Gupta, CEO of Cardlytics. "We remain grounded in our vision for long-term and sustainable growth. We are focused on strengthening our competitive moat through our efforts to modernize our platform, enhance our product and tech capabilities, and expand our network of partners and advertisers." "In 2025, we are focused on delivering sequential improvements and positive Adjusted EBITDA," said Alexis DeSie

      3/12/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hill Scott A bought $143,200 worth of shares (40,000 units at $3.58) (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:46:37 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Director Hornsey Liane bought $35,900 worth of shares (10,000 units at $3.59) (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:45:56 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Director Klinck John L. Jr. bought $48,860 worth of shares (14,000 units at $3.49), increasing direct ownership by 26% to 67,593 units (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:39:19 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cardlytics Announces First Quarter 2025 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2025. "We've made marked progress across our key business pillars, which continue to underpin our journey to 'platformize' Cardlytics and position ourselves as the leading commerce media platform," said Amit Gupta, CEO of Cardlytics. "Our expanding ecosystem, depth and breadth of our data, and ongoing tech investments are strengthening our position and providing differentiated value to our partners and advertisers." "We've built a resilient platform and are making strategic decisions as we look to future-proof our business," said Alexis DeSieno, CFO of Ca

      5/7/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

      Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

      4/30/25 9:00:00 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Cardlytics, Inc. (NASDAQ:CDLX) today announced that on April 24, 2025, the Compensation Committee of Cardlytics' Board of Directors granted an aggregate of 124,050 restricted stock units of Cardlytics to 11 newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the "2022 Inducement Plan"). For all of the grant recipients, 50% of the restricted stock units shall vest on the first anniversary of the grant date, and the remaining 50% shall vest quarterly over the subsequent 12 months, subject to the employees' continu

      4/25/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on Cardlytics with a new price target

      Evercore ISI initiated coverage of Cardlytics with a rating of In-line and set a new price target of $4.00

      10/11/24 8:36:58 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics downgraded by Northland Capital with a new price target

      Northland Capital downgraded Cardlytics from Outperform to Market Perform and set a new price target of $5.00

      8/16/24 8:54:02 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cardlytics from Neutral to Underperform and set a new price target of $3.50 from $4.00 previously

      8/15/24 7:18:52 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Leadership Updates

    Live Leadership Updates

    See more
    • TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

      Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

      4/30/25 9:00:00 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • 23andMe Appoints Three New Independent Directors to Board

      SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

      10/29/24 7:30:00 AM ET
      $ANSS
      $CDLX
      $LSCC
      $ME
      Computer Software: Prepackaged Software
      Technology
      Computer Software: Programming Data Processing
      Semiconductors
    • Cardlytics Appoints Amit Gupta as CEO

      ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced that the Board of Directors has appointed Amit Gupta, Chief Operating Officer and General Manager of Bridg, as its next Chief Executive Officer of Cardlytics, effective August 16, 2024. He will also join the Cardlytics Board of Directors on that date. Mr. Gupta will succeed Karim Temsamani, who is stepping down as Chief Executive Officer and from the Board of Directors to pursue another professional opportunity. "Amit is the right person to lead Cardlytics in its next stage of growth," said Jack Klinck, Chair of the Cardlytics Board. "For the last year and a half, Ami

      8/7/24 4:10:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cardlytics Inc.

      10-Q - Cardlytics, Inc. (0001666071) (Filer)

      5/7/25 4:30:52 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cardlytics, Inc. (0001666071) (Filer)

      5/7/25 4:07:09 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form DEFR14A filed by Cardlytics Inc.

      DEFR14A - Cardlytics, Inc. (0001666071) (Filer)

      4/29/25 4:02:21 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Cardlytics Inc.

      SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

      7/2/24 7:05:14 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

      SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

      3/29/24 5:05:56 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

      SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

      3/18/24 7:46:57 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer converted options into 682 shares and sold $458 worth of shares (303 units at $1.51), increasing direct ownership by 0.37% to 102,119 units (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      4/22/25 8:27:13 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Director Hornsey Liane converted options into 1,326 shares, increasing direct ownership by 13% to 11,326 units (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      4/9/25 4:04:33 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Chief Executive Officer Gupta Amit converted options into 14,350 shares and sold $13,260 worth of shares (7,342 units at $1.81), increasing direct ownership by 2% to 371,080 units (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      4/3/25 4:12:45 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology